What ZYUS does

ZYUS Life Sciences Corporation is a publicly traded clinical-stage biopharmaceutical company headquartered in Saskatoon, Saskatchewan, Canada, listed on the TSX Venture Exchange under ticker ZYUS. Founded in 2018, the company develops proprietary, non-opioid, non-intoxicating cannabinoid-based pharmaceutical drug candidates targeting pain management indications where the current standard of care relies heavily on opioid analgesics. Its lead asset is Trichomylin®, a proprietary softgel capsule drug candidate under clinical evaluation in the Phase 2a UTOPIA-1 trial (NCT06533657) for moderate to severe cancer-related pain, with preliminary data (Jan 2026) showing reductions in daily pain, pain interference, pain severity and opioid dosing with no serious drug-related adverse events. A second drug candidate based on a Cannabichromene (CBC) formulation targets neuropathic pain conditions including diabetic and cancer-related neuropathies, supported by the issuance of U.S. Patent No. 12,616,704 in May 2026 (the company's second U.S. pain management patent), with IND-enabling studies completed.

The company's business model combines two distinct streams: a direct-to-consumer exempt market medical cannabis operation in Canada via the zyus.ca storefront (selling cannabinoid formulations to registered patients and caregivers with a Medical Document Form), and pre-revenue pharmaceutical drug development awaiting regulatory approval. Distribution is currently single-country (Canada), with future pharmaceutical commercialization expected post-regulatory approval. In June 2026, the company announced a strategic realignment discontinuing international business development and winding down international legal entities to refocus resources on core U.S./Canadian drug development priorities, alongside the departure of long-tenured CSIO Keith Carpenter.

With 51-100 employees, no commercial pharmaceutical product, and capital raised primarily through small private placements and insider-supported debt (notably a C$1.5 million loan from independent director Wayne Brownlee in October 2025 and a C$2 million revolving facility from CEO Brenton H. Zettl), ZYUS operates as an early-stage clinical biotech dependent on continued capital access. ZYUS is also covered by Stifel GMP analyst Justin Keywood on the sell-side and reports audited results through SEDAR+ as a TSXV-listed reporting issuer.

Name

ZYUS

Legal name

ZYUS Life Sciences Corporation

Website

https://zyus.com

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Short description

ZYUS Life Sciences Corporation is a clinical-stage Canadian biopharmaceutical company developing proprietary non-opioid, non-intoxicating cannabinoid-based drug candidates (Trichomylin® and a CBC formulation) for cancer-related and neuropathic pain, while selling exempt market medical cannabis in Canada via zyus.ca.

Ownership category

akta.pro rank

Product category

Clinical-Stage Biopharmaceutical Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Pharmacies and Drug Retailers (456110)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

akta.pro secondary industries

Medical Cannabis Dispensaries (CRANAFAB), Pain Medicine (Interventional/Neuropathic Pain) (HLAKAIAM)

Keywords

• Cannabinoid therapeutics
• Non-opioid pain management
• Clinical-stage biopharmaceutical
• Medical cannabis products
• Oncology pain research

Headquarters

HQ city

Saskatoon

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Medical cannabis product sales (exempt market): ZYUS Life Sciences Corporation and its subsidiaries sell exempt market cannabinoid formulations and medical cannabis products in Canada through the zyus.ca commercial website to registered patients and caregivers, generating transactional product revenue.
2. Future pharmaceutical drug commercialization (pre-revenue): Currently pre-revenue on the pharmaceutical pipeline. Future revenue expected from commercialization of non-opioid cannabinoid-based prescription drug candidates (Trichomylin®, CBC formulation) targeting regulatory approval for pain management indications in oncology and neuropathic pain.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Core offering

ZYUS Life Sciences Corporation is a clinical-stage biopharmaceutical company developing proprietary, non-opioid, non-intoxicating cannabinoid-based drug candidates for pain management. Its lead asset, Trichomylin® softgel capsules, is being evaluated in the Phase 2a UTOPIA-1 trial for moderate to severe cancer-related pain, alongside a second Cannabichromene (CBC) formulation drug candidate targeting neuropathic pain. The company also generates current revenue from selling exempt market medical cannabis formulations in Canada directly to registered patients through the zyus.ca online storefront.

Product overview

ZYUS Life Sciences Corporation is a single clinical-stage pharmaceutical company built around a unified non-opioid pain management pipeline, rather than a platform-plus-modules architecture. Its core offering consists of the Trichomylin® softgel capsules lead drug candidate (evaluated in the Phase 2a UTOPIA-1 trial and previously in the Phase 1 Z-TRI-10001 trial) and a second Cannabichromene (CBC) formulation drug candidate for neuropathic pain, supplemented by commercial Exempt Market Formulations distributed via the zyus.ca online store under the Canadian Cannabis Act. The Trichomylin® and CBC assets together form the proprietary drug development portfolio, while ZYUS.ca functions as the company's patient-facing commercial channel for currently approved medical cannabis products.

Differentiator

Problem solved

Functional benefit

Brands

• Trichomylin: ZYUS's lead pharmaceutical product candidate - softgel capsules being evaluated in the Phase 2a UTOPIA-1 trial for cancer-related pain and in development for neuropathic pain conditions including diabetic and cancer-related neuropathies; a novel non-opioid, non-intoxicating cannabinoid-based formulation.

Products and services

• Trichomylin® Softgel Capsules ZYUS's lead pharmaceutical drug candidate, a proprietary non-opioid, non-intoxicating cannabinoid-based softgel capsule being evaluated for moderate to severe cancer-related pain and intended for non-opioid pain management in oncology and related indications.
• Cannabichromene (CBC) Formulation for Pain Management ZYUS's second pharmaceutical drug candidate, a novel non-intoxicating Cannabichromene (CBC) formulation covered by U.S. Patent No. 12,616,704, in IND-enabling studies targeting neuropathic pain conditions including diabetic and cancer-related neuropathies.
• Exempt Market Medical Cannabis Formulations Cannabinoid-based medical cannabis formulations sold under Canada's exempt market framework through the zyus.ca online storefront to registered Canadian patients and caregivers who hold a Medical Document Form from a health care practitioner, generating current transactional product revenue for the company.

Quantifiable outcome

• Phase 2a UTOPIA-1 trial preliminary data (first 25% of enrolled patients) showed reductions in average daily pain, pain interference, and pain severity, as well as reduced opioid dosing for breakthrough cancer pain, with no serious adverse events related to the drug.
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

One partnership is on record.

• Clinical trial sites and investigators (Phase 2a UTOPIA-1 trial, NCT06533657)coreStrategic or Co-development PartnerZYUS is conducting the Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial evaluating Trichomylin® softgel capsules in patients with moderate to severe cancer-related pain. The trial is registered on clinicaltrials.gov as NCT06533657 and is led by Chief Medical Officer Dr. Julie Stakiw. Dr. Stakiw commented on the preliminary results in the January 8, 2026 press release.

Scale indicators13 records

Recent moves7 records

Expansion highlights3 records

Broad incumbents

• Jazz Pharmaceuticals: Jazz Pharmaceuticals owns Epidiolex, the first FDA-approved plant-derived cannabinoid prescription drug, establishing the regulatory pathway ZYUS is targeting. As a profitable specialty pharma with established cannabinoid commercialization infrastructure, it is the most relevant comparable for cannabinoid-pharma execution and BD optionality.
• Pfizer: Global pharmaceutical leader with a substantial pain management portfolio and large R&D budget actively pursuing non-opioid alternatives. Represents both the competitive threat and the potential BD/licensing counterparty for ZYUS's cannabinoid pain candidates.

Direct peers

• InMed Pharmaceuticals: Clinical-stage biopharmaceutical company developing cannabinoid-based therapies (including rare disease and pain/epidermolysis bullosa indications). Comparable to ZYUS as a small-cap cannabinoid drug developer pursuing FDA-regulated indications.
• Corbus Pharmaceuticals: Clinical-stage pharma historically focused on cannabinoid-derived therapeutics (lenabasum) for inflammatory and fibrotic diseases. Direct competitor in the cannabinoid-pharma category, sharing similar regulatory pathway and small-cap clinical-development risk profile.
• Tetra Bio-Pharma: Canadian clinical-stage pharmaceutical company developing cannabinoid-based prescription drugs for pain and oncology indications. Closest direct Canadian peer to ZYUS with overlapping cannabinoid pain pipeline and similar regulatory approach.

Emerging players

• Aurora Cannabis: Canadian-licensed medical cannabis producer with a portfolio of medical cannabis products distributed through its patient platform. Comparable as a Canadian medical cannabis operator, though without ZYUS's clinical-stage pharmaceutical pipeline.
• Canopy Growth: Major Canadian cannabis producer with a medical cannabis platform (Spectrum Therapeutics) and historical cannabinoid pharmaceutical research initiatives. Adjacent peer in medical cannabis with broader scale and brand reach than ZYUS.
• Tilray Brands: Large Canadian cannabis company with a medical cannabis division selling pharmaceutical-grade products and pursuing cannabinoid-based pharmaceutical opportunities. Comparable as a competitor in the medical cannabis and cannabinoid pharma space, though substantially larger and more diversified than ZYUS.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/ZYUSInc
• LinkedInlinkedin.com/company/zyuslifesciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds17 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ZYUS